You just read:

Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration

News provided by

Regeneron Pharmaceuticals, Inc.

30 Sep, 2016, 07:00 ET